Alector Inc. reported a net loss of $34.7 million, or $0.34 per share, for the quarter ended September 30, 2025, compared to a net loss of $42.2 million, or $0.43 per share, in the same period in 2024. General and administrative expenses for the quarter were $11.5 million, down from $15.8 million in the prior year period, primarily due to the absence of impairment charges and reduced personnel-related costs. As of September 30, 2025, cash, cash equivalents, and investments totaled $291.1 million, including $14.7 million raised through at-the-market equity offerings in September, and an additional $5.3 million raised in October. The company expects this cash position to fund operations through 2027. Guidance for 2025 includes collaboration revenue between $13.0 million and $18.0 million, research and development expenses between $130.0 million and $140.0 million, and general and administrative expenses between $55.0 million and $65.0 million. Key business developments include selection of lead candidates AL137 for Alzheimer's disease and AL050 for Parkinson's disease, advancement of various ABC-enabled programs, and plans for an interim analysis of the Phase 2 PROGRESS-AD trial in early 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alector Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569922-en) on November 06, 2025, and is solely responsible for the information contained therein.
Comments